MRK - Merck & Co Inc
A global pharmaceutical leader whose Keytruda cancer immunotherapy is the best-selling drug in the world, supporting a robust oncology and vaccines pipeline.
Finlify Score
50.1 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$143.93
-0.54%
52W Range
$77.58 - $156.92
Market Cap
$364.5B
-0.5%Compared to previous day
2026 Q1 Revenue
$16.3B
-0.7%Changes from last reporting quarter
2026 Q1 EPS
$-1.72
Diluted shares
Analyst Rating
36 analysts in latest ratings feed
RSI
35.3
<40 oversold
2Y Range Position
84%
-8.3% from high / +96.3% from low
Beta
0.15
Relative to market benchmark
MACD
-1.41
MACD line 3.35 / signal line 4.76
Fundamental Trend
Growth 6.1Financial Health
Quality 27.9Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD50.1 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $16.3B-0.7% | $16.4B-5.1% | $17.3B+9.3% | $15.8B+1.8% |
| Gross Profit | - | - | - | - |
| Operating Income | - | - | - | - |
| Net Income | -$4.2B-243.1% | $3.0B-48.8% | $5.8B+30.7% | $4.4B-12.8% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Aug 1, 2026
The Finlify signal for MRK is an "AVOID" with a Finlify Score of 35.6 out of 100. This stance appears to be largely influenced by very low Fundamental Trend and Financial Quality scores, despite some positive technical indicators.
Technical
While Relative Strength is robust at 64.9/100 and the asset has shown strong recent performance with a 60-day return of 14.7% and a 20-day return of 3.5%, the Accumulation / Volume score is weaker at 36.6/100. The RSI(14) of 57.8 suggests neutral to slightly strong momentum, and the stock is trading close to its 52-week high, only -1.5% away.
Fundamentals
The Fundamental Trend score is notably low at 6.1/100, which may indicate a deteriorating outlook for key financial metrics, and Financial Quality also appears weak at 27.9/100. Valuation metrics show a P/E of 17.7x, P/B of 5.0x, and P/S of 5.0x. MRK exhibits a low Beta of 0.2, suggesting lower volatility, and offers a dividend yield of 2.62%.
Macro Context
In a macro environment with a 10Y Treasury Yield at 4.7% and a 2Y Treasury Yield at 4.2%, the positive yield spread of 0.5% may suggest a less immediate risk of recession, potentially supporting equity markets generally. However, persistent inflation indicated by CPI YoY at 3.7% and Core PCE YoY at 3.3% could impact input costs or consumer spending, which might affect pharmaceutical companies like MRK.
Key Risks
- The very low Fundamental Trend score of 6.1/100 suggests significant underlying fundamental deterioration.
- A Financial Quality score of 27.9/100 indicates potential concerns regarding the company's financial health or efficiency.
- With earnings scheduled for 2026-08-04, there is inherent volatility risk surrounding the announcement.